Corporate ActionJun 22, 2026, 04:01 PM
MoonLake Announces Proposed $150M Public Offering of Shares
AI Summary
MoonLake Immunotherapeutics announced a proposed public offering aiming to raise $150 million through Class A ordinary shares and pre-funded warrants. The underwriters will also have a 30-day option to purchase up to an additional $22.5 million in shares. The company intends to use the net proceeds to fund the research, development, pre-commercialization, and commercialization activities of sonelokimab, if approved, and for general corporate purposes.
Key Highlights
- MoonLake announced a proposed public offering to raise $150 million.
- Offering includes Class A ordinary shares and pre-funded warrants.
- Underwriters have a 30-day option to purchase an additional $22.5 million in shares.
- Net proceeds will fund research, development, and commercialization of sonelokimab.
- Proceeds will also be used for general corporate purposes.
- Leerink Partners, Guggenheim Securities, Cantor, and LifeSci Capital are joint bookrunning managers.
Price Impact
More from MLTX